Abstract 764P
Background
Tislelizumab is an investigational, humanized, IgG4 monoclonal antibody with high affinity and binding specificity for programmed cell death-1 (PD-1) emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase II trial evaluated the combination of Tislelizumab plus definitive chemoradiotherapy in patients with recurrent and/or metastatic cervical cancer who relapsed after prior platinum-based therapy.
Methods
PILOT-2020-511 was a single-arm, phase 2 trial done at Fudan University Shanghai Cancer Center (Shanghai, China). Patients aged 18-70 years with recurrent and/or metastatic cervical cancer, with an ECOG performance status of 0-2, and adequate organ and bone marrow function were eligible for inclusion. Patients received concurrent radiotherapy (58-60 Gy in 28 fractions), chemotherapy (4-6 cycles of intravenous paclitaxel [135 mg/m2] and carboplatin [AUC=5]), and tislelizumab (200 mg intravenously every 3 weeks for up to 1 year, or until disease progression or unacceptable toxicity). The primary endpoint was the complete response rate at 3 months after radiotherapy by investigator assessment. Secondary endpoints were overall survival, progression-free survival, duration of response, quality of life (not reported here), and safety. The trial is registered with Chictr.org.cn, ChiCTR2000034748 and follow-up is ongoing.
Results
Between September 1, 2020, and December 25, 2022, 41 patients were enrolled. The median age was 58 years (IQR 52-67), 30 (73.2%) of 42 patients had lymphatic metastasis, and 11 (26.8%) patients were organic metastasis. 40 (97.6%) of 41 patients completed the planned chemoradiotherapy and 32 (78%) of 41 had a complete response. The 1-year overall survival was 66.8% and 1-year progression-free survival was 61.8%. The most common grade 3 or worse adverse event was lymphopenia. The most common immune-related adverse event was thyroid dysfunction.
Conclusions
Combining Tislelizumab with definitive chemoradiotherapy provided encouraging activity and acceptable toxicity in patients with recurrent and/or metastatic cervical cancer, and this regimen warrants further investigation.
Clinical trial identification
ChiCTR2000034748.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Presenter: Alessandro Parisi
Session: Poster session 11
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11